A l e k s a n d r a M o ś c i c k a - S t u d z i ń s k a

INNOMED PROGRAMME

8th December 2016

TO G E T H E R F O R I N N O VAT I O N I N H E A LT H

INNOMED Programme

Medical and Health Projects in NCBR

National Initiatives

Prevetion practices and treatment of civilization diseases STRATEGMED

INNOMED

Applied Research Programme

Technology Initiative and Initech Programmes

Scientific Solicited Projects

Scientific Development Projects

Programme LIDER

GO_GLOBAL

INITECH

INNOTECH

DEMONSTRATOR BIO-INFO

International Initiatives

FRAMEWORK PROGRAMMES

(ERA-NETs, JU, JPI)

AAL JP

EuroNanoMed II

NEURON

TRANSCAN

Infect-Era

PRIOMEDCHILD

E-RARE

JPND

JPI HDHL DEDIPAC KH

EUREKA

EUROSTARS

AMR

HORIZON 2020

JPco-fuND

TRANSCAN-2

E-Rare-3

Neuron Cofund

EuroNanoMed III

ERA-CVD

ERA HDHL

BILATERAL COOPERATION

Polish – Norwegian (small grant scheme,

Core 2012)

Polish - Singapore

Polish - Taiwanese

INNOMED Programme

• initiated by the agreement between the Polish Innovative Medicine Technology Platform (PPTIM) and the National Centre for Research and Development.

According to the agreement the contribution of the NCBR is up to 65% of the programme budget, the rest shall be financed by programme participants.

• call topics are defined by Steering Committee that consist of members nominated by the Polish Innovative Medicine Technology Platform, the Director of the National Centre for Research and Development and the Board of the National Centre for Research and Development.

• established in 2012 year as a sectoral domestic programme.

The objectives of the INNOMED Programme are:

• Improvement the competitiveness of the Polish economy and increasing the availability of high-technology medical products for patients in Poland.

• Increasing the number of developed and implemented innovative technologies in Poland.

• Strengthening cooperation between research groups possessing a proper know-how and research infrastructure and R & D departments of pharmaceutical companies.

Thematic scope:

innovative drugs; development of innovative medicinal products and therapies; personalization of therapy and prevention; innovative technologies of generics manufacturing.

Programme schedule:

From 2013 up to 2015 - 2 calls for proposals From 2014 up to 2020 - financing and monitoring of the selected projects to 2026 - follow-up of the result implementation into the market

Programme budget:

300 M PLN (approx. 68 M€) out of which: 195 M PLN - contribution of the NCRD 105 M PLN - contribution of programme participants

Research projects:

Duration max. 5 years Funding 1-10 M PLN (40-80% of eligible costs depends on state aid level) Obligation to project result implementation

INNOMED Programme

1st call results:

• 17 projects

• 191 M PLN total projects budget (110 M PLN grant-aid + 81 M PLN own contribution)

• Beneficiaries (12 consortia and 5 individual projects):

5 large enterprises,

17 SMEs,

20 partners from academia.

2nd call results:

• 10 projects

• 93 M PLN total projects budget (58 M PLN grant-aid + 35 MPLN own contribution)

• Beneficiaries (1 consortium and 9 individual projects):

3 large enterprises,

8 SMEs.

INNOMED Programme

1st call

Source of financing: the Innovative Economy Operational Program and domestic funds

Examples of projects:

KIND-P1: Introduction of novel, selective, anticancer kinase inhibitors into clinical trials.

ONKOFAG: Development of phage therapy and its application in the treatment of antibiotic-resistant infections with a focus on cancer patients .

BRASTER_UJCM: Development of an internationally innovative Tester BRASTER device for digital registration of thermography images of women's mammary gland pathologies and clinical trial comparing the efficiency of the device against standard breast cancer diagnostic methods .

ONKIN: The development of innovative technology for producing anticancer drug - androgens biosynthesis inhibitor.

BIOCON: Next generation anticancer bioconjugates.

INNOMED Programme

2nd call

Source of financing: Smart Growth Operational Programme (Priority Axis: - I Support for R&D activity of enterprises)

Examples of projects:

ECONIB: Enhancing the diagnostic efficiency of dynamic contrast -enhanced imaging in personalised oncology by extracting new and improved biomarkers.

WIND-P0: Preclinical and clinical studies on drug candidate compounds revealing anticancer activity

MultiSom: Multivariate formulations of DOTATATE peptide as precursor for preparation of radiopharmaceuticals

ARAS: Development of anticancer targeted therapy based on small molecules regulating mutated RAS protein G12V

INNOMED Programme

2nd call statistics

INNOMED Programme

Field of science and technology by the OECD Number of

selected projects

3.1.e Pharmacology and pharmacy 3

3.4.c Technologies involving identyfying the functioning of DNA, proteins and enzymes… 2

2.6.a Medical engineering 2

3.1.f Medicinal chemistry 1

3.2.l Radiology, nuclear medicine and medical imagining 1

3.4.a Health-related biotechnology 1

Place of realisation Number of selected projects

Masovian 4

Łodz 2

Silesian 2

Lesser Poland 1

Lower Silesian 1

First implementation…

BRASTER_UJCM: Development of an internationally innovative Tester BRASTER device for digital registration of thermography images of women's mammary gland pathologies and clinical trial comparing the efficiency of the device against standard breast cancer diagnostic methods.

• product available from October 2016 (device and application for telemedical system)

• funding: 9 097 795,49 PLN

INNOMED Programme

InnoNeuroPharm: programme for neuromedicine and pharmaceutical sectors

• Established in cooperation of:

the Polish Association of the Pharmaceutical Industry Employers

and

Polish Platform of Innovative Neuromedicine - INONEUROMED

• 190 mln PLN - call allocation

• 20th January 2017 - 1st call announcement

• 22nd February 2017 - start of proposals submission

INNONEUROPHARM Programme

EuroNanoMed is an ERA-NET on Nanomedicine established since 2008 as a platform for funding agencies and ministries to coordinate research programmes with the goal of creating and funding collaborative research and innovation projects that can convert research in nanotechnology into practical gains in medicine.

EuroNanoMed I I I cofund

Through 7 successful Joint Transnational Calls launched from 2009 to 2016, EuroNanoMed has allocated about 55 Million euros to fund 60 transnational projects in nanomedicine.

EuroNanoMed III (2016-2020) is the new ERA-Net Cofund Action on Nanomedicine under Horizon 2020 that will build upon the achievements on its predecessors to support the European Nanomedicine research community.

• 25 partners

• 19 countries/regions

• From Nov. 2016 to Oct. 2021

EuroNanoMed I I I cofund

The 8th Joint Transnational Call is now opened for funding multilateral innovative research projects on nanomedicine:

• Submission deadline for pre-proposals: 16th January 2017; Submission deadline of full proposals: 9th June 2017;

• Project proposals will need to cover at least one of the following areas:

Regenerative medicine

Diagnostics

Targeted delivery systems

• Consortium submitting a proposal will need to involve a minimum of 3 eligible and a maximum of 5 eligible partners from at least 3 different countries participating to the call (detailed information and call documents available on www.euronanomed.net)

• Alocation of the NCRD for Polish partners is 700 000 EUR; eligible to apply are: SMEs and large enterprise, as well as research organizations, but the consortium will need to involve at least one Polish enterprise to be eligible for funding Polish applicants from academia.

Looking for partners? - see the Nanomed Map: http://www.etp-nanomedicine.eu/public/nanomedmap/

and partner search tool available on www.euronanomed.net

EuroNanoMed I I I cofund

Country Funding Organisation Contact point Email

Belgium FNS-FNRS Arnaud Goolaerts arnaud.goolaerts@frs-fnrs.be

Canada (Québec) FRQS Karine Genest Anne-Cécile Desfaits

Karine.genest@frq.gouv.qc.ca Annececile.desfaits@frq.gouv.qc.ca

Estonia ETAg Aare Ignat Aare.ignat@etag.ee

France ANR Amélie Vergne ENMCalls@anr.fr

Germany VDI Technologiezentrum GmbH Alexandra Brennscheidt brennscheidt@vdi.de

Greece GSRT Paraskevi Afentaki pafe@gsrt.gr

Ireland SFI Louise Rocks louise.rocks@sfi.ie

Israel CSO-MOH Irit Allon Irit.allon@moh.gov.il

Italy IMH Gaetano Guglielmi g.guglielmi@sanita.it research.eu.dgric@sanita.it

Italy MIUR Aldo Covello Andrea Pompozzi

aldo.covello@miur.it andrea.pompozzi@miur.it

Latvia VIAA Linda Vecbiskena Linda.Vecbiskena@viaa.gov.lv

Lithuania RCL Laura Kostelnickienė laura.kostelnickiene@lmt.lt

The Netherlands STW Melvin Kasanrokijat m.kasanrokijat@stw.nl

Norway RCN Cecilie A. Mathiesen cam@rcn.no

Poland NCBR Aleksandra Mościcka-Studzińska aleksandra.moscicka@ncbr.gov.pl

Romania UEFISCDI Mihaela Manole mihaela.manole@uefiscdi.ro

Slovakia SAS Katarina BIBOVA Jan BARANCIK

bibova@up.upsav.sk barancik@up.upsav.sk

Spain MINECO Carles Cané Leonor Gómez

era-nano@mineco.es

Spain ISCIII María Druet mdruet@isciii.es

Spain CDTI Juan Luis Romera juanluis.romera@cdti.es

Taiwan MOST Louis Chen ymchen@most.gov.tw

Turkey TUBITAK Mahmut OZER mahmut.ozer@tubitak.gov.tr

Thank you!

www.ncbr.gov.pl

aleksandra.moscicka@ncbr.gov.pl